Loading...
•
Jun 30, 2025
Revolution Medicines Q2 2025 Earnings Report
Revolution Medicines reported second quarter 2025 results
Key Takeaways
Revolution Medicines reported a net loss driven by high R&D and G&A expenses, supported by a strong cash position from a funding agreement.
Net loss of $247,787,000 for Q2 2025
Loss from operations of $264,714,000
R&D expenses of $224,134,000, up from prior year
Cash, cash equivalents and marketable securities of $2,137,171,000 at quarter end
Forward Guidance
Full year 2025 GAAP net loss guidance of $1.03 billion to $1.09 billion, including $115 million to $130 million of stock-based compensation expense.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...